Stock futures lower as countdown to Yellen speech begins

Nomura Securities Raises Price Target on Tiffany & Co. (TIF) Following Better-Than-Expected 2Q

Nomura Securities reiterated a Buy rating on Tiffany & Co. (NYSE: TIF), and raised the price target to $76.00 (from $64.00), following the company's 2Q earnings report. TIF posted meaningfully better-than-expected GMs in 2Q for a third straight quarter of >200bp expansion. The beat allowed management... More

EPS Beat Improves Cowen's Confidence on Tiffany & Co. (TIF); Reiterates Market Perform

Cowen reiterated a Market Perform rating on Tiffany & Co. (NYSE: TIF), and raised the price target to $74.00 (from $68.00), following the company's 2Q earnings report. TIF reported a worldwide comp decline of -9% C/C, partly attributed to lower tourist spending. However, a $0.12 EPS beat... More

Mizuho Securities Raises Price Target on Tiffany & Co. (TIF) to $82 Following Solid 2Q Beat

Mizuho Securities reiterated a Buy rating on Tiffany & Co. (NYSE: TIF), and raised the price target to $82.00 (from $72.00), following the company's 2Q earnings report. TIF reported EPS of $0.84, above the consensus estimates of $0.62. The beat was driven by SG&A control and stabilization in select... More

Brean Capital Raises Price Target on Workday (WDAY) to $62; Reiterates Sell

Brean Capital maintained a Sell rating on Workday (NYSE: WDAY), and raised the price target to $62.00 (from $55.00), following the company's 2Q earnings report. WDAY's F2Q billings grew 38%, beating Street growth estimates of 35%. Much of the billings upside was driven by strong sequential growth in short-term deferred revenue. Overall, Brean Capital believes that WDAY's business is benefiting from reacceleration in its core HCM business, solid execution in the international markets and solid traction for the... More

UBS Reiterates Buy on Workday (WDAY) Following Mixed 2Q Results

UBS reiterated a Buy rating on Workday (NYSE: WDAY), and raised the price target to $94.00 (from $86.00), following the company's 2Q. WDAY reported revenues of $378M, ahead of the Street's $373M estimate. EPS came in at -$0.04, missing -$0.02 estimates.

Analyst Brent Thill commented, "FQ2 metrics, deal... More

Jefferies Raises Price Target on Workday (WDAY) to $72 Following Mixed 2Q

Jefferies reiterated a Hold rating on Workday (NYSE: WDAY), and raised the price target to $72.00 (from $68.00), following the company's 2Q earnings report. Non-GAAP EPS of ($0.04) was below consensus of ($0.02) due to a one-time write-off which impacted EPS by $0.07. Total revenues of $377.7M were better than... More

Jefferies Says No Changes to Ests on Amgen (AMGN) Amid Parsabiv CRL; Affirms at 'Buy'

Jefferies affirms Amgen (Nasdaq: AMGN) with a Buy rating and $198 price target following receipt of FDA CRL on Parsabiv.

The firm commented, On positive Ph3 data, FDA approval of Parsabiv for treatment of secondary hyperparathyroidism was largely expected. Details of the CRL is... More

Wedbush Reiterates Underperform on Workday (WDAY) Following Solid 2Q

Wedbush maintained an Underperform rating on Workday (NYSE: WDAY), and raised the price target to $69.00 (from $63.00), following the company's 2Q earnings report. WDAY reported a $5M revenue beat and strong billings.

Analyst Steve Koenig commented, "WDAY saw strong 2Q billings and a solid revenue beat stemming... More